Sodium-glucose cotransporter-2 (SGLT2) inhibitor, an antihyperglycemic medication, reduces the risk of hospitalization for heart failure patients and cardiovascular death, which makes it unique compared to other medications in this category [7]. Among the available SGLT2 inhibitors in the market, empagliflozin had a low cost needed to treat diabetic patients for primary prevention compared to other agents [8]. The gene discussed is SLC5A2; the disease is heart failure.